JACC: CardioOncology September 01, 2019 | Vol. 1 No. 1 – Table of Contents of this issue
ARTICLES IN THIS ISSUE (open access):
- ORIGINAL RESEARCH: Safety of Continuing Trastuzumab Despite Mild CardiotoxicityA Phase I Trial – Darryl P. Leong, Sukhbinder Dhesy-Thind, et al.
- EDITORIAL COMMENT: Trastuzumab Cures Cancer and Disrupts the Practice of Cardiology – Richard M. Steingart, Chau T. Dang, et al.
- Renin-Angiotensin-Aldosterone System Modulates Blood Pressure Response During Vascular Endothelial Growth Factor Receptor Inhibition – Wendy J. Bottinor, Evan L. Brittain, et al.
- Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor – Sarah Waliany, Ronald M. Witteles, et al.
- EDITORIAL COMMENT: Hypertension and AntiangiogenesisThe Janus Face of VEGF Inhibitors – Rhian M. Touyz and Ninian N. Lang
- Pre-Diagnosis Exercise and Cardiovascular Events in Primary Breast CancerWomen’s Health Initiative – Tochi M. Okwuosa, Lee W. Jones, et al.
- EDITORIAL COMMENT: Exercise and Cardiovascular Outcomes in Older Women With Breast CancerThe Heart of the Matter – Lindsay L. Peterson and Jennifer A. Ligibel
- Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy – Muthiah Vaduganathan, Ambarish Pandey, et al.
- EDITORIAL COMMENT: Cardioprotection From CardiotoxicityThe Quest for the Holy Grail Goes On – Guilherme H. Oliveira
- Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer – Ariane V.S. Macedo, Antonio L.P. Ribeiro, et al.
- EDITORIAL COMMENT: Overcoming Inertia to Tame the Red Devil – Christine E. Simmons
- Prokineticin Receptor-1 Signaling Inhibits Dose- and Time-Dependent Anthracycline-Induced Cardiovascular Toxicity Via Myocardial and Vascular Protection – Adeline Gasser, Canan G. Nebigil, et al.
- EDITORIAL COMMENT: Prokineticin-izing Doxorubicin-Damaged Hearts – Emilio Hirsch
- STATE-OF-THE-ART REVIEWS: The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity – Lori M. Minasian, Bonnie Ky, et al.
- VIEWPOINT: Birth and Maturation of Cardio-Oncology – Deepak L. Bhatt
- VIEWPOINT: AL Amyloidosis for the Cardiologist and OncologistEpidemiology, Diagnosis, and Management – Ronald M. Witteles and Michaela Liedtke
- EDITOR’S PAGE: JACC: CardioOncology: Poised to Serve a Maturing, Collaborative Field – Bonnie Ky
- LEADERSHIP PAGE: Cardio-OncologyStronger Together – Richard J. Kovacs and Howard A. Burris
- RESEARCH LETTERS: Incidental Coronary Artery Calcification in Cancer Imaging – Sarah Cuddy, John D. Groarke, et al.
- RESEARCH LETTERS: Current Management of Symptomatic Pericardial Effusions in Cancer Patients – Audrey Besnard, Nicolas Amabile, et al.
- CLINICAL CASE CHALLENGES: Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock – Osnat Itzhaki Ben Zadok, Tuvia Ben Gal, et al.
CATEGORY
Cardio-oncologia in generaleanno pubblicazione 2019Cardiotossicità da anti-HER2Cardiotossicità da antraciclineCardiotossicità da trattamenti antineoplasticiCardiotossicità e disfunzione al ventricolo sinistroCardiotossicità e ipertensioneCardiotossicità e ischemia cardiacaCaso clinicoFOCUS ON: ESC & JACCGenerale
Cardio-oncologia in generaleanno pubblicazione 2019Cardiotossicità da anti-HER2Cardiotossicità da antraciclineCardiotossicità da trattamenti antineoplasticiCardiotossicità e disfunzione al ventricolo sinistroCardiotossicità e ipertensioneCardiotossicità e ischemia cardiacaCaso clinicoFOCUS ON: ESC & JACCGenerale